Enavogliflozin after TAVR for heart narrowing with mild heart weakness
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests enavogliflozin (a diabetes medication that may help the heart) in people who have had a TAVR procedure for severe aortic stenosis. It looks at whether the medicine can improve outcomes for people with symptoms and mildly reduced or preserved pumping function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 19 years old and had TAVR successfully for severe aortic stenosis
- Your heart symptoms are present, and your valve placement after TAVR was considered successful with no major complications
- Your heart pumping strength is mildly reduced or mostly preserved (ejection fraction 40% or higher)
- You have signs of heart strain, like thick heart muscle or an enlarged left heart chamber, and a blood marker (NT-proBNP) above a threshold
- You have not taken an SGLT2 inhibitor in the last 4 weeks, and you don’t have an allergy to this medicine class
- You are not currently in a dangerous heart failure flare and you don’t have certain kidney, urine infection, stroke timing, blood pressure, or diabetes conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a new through-the-blood-vessel heart valve (TAVR) is safe and works well for people with severe aortic stenosis who are too risky for traditional surgery. If you qualify, you would be closely followed to check your symptoms and valve function over time.
This trial tests a new heart valve replacement (TAVR) system in people with severe, symptomatic aortic stenosis. If you qualify, it may offer a less invasive option compared with open-heart valve surgery, while also helping researchers understand safety and early effectiveness.
This study compares regular monitoring (“clinical surveillance”) versus replacing the aortic valve using a minimally invasive procedure called TAVR for people with moderate aortic stenosis. It aims to see which approach better reduces symptoms or heart damage over time.
This trial studies how safe and effective the NAVITOR valve is for treating narrowed aortic valves placed through a catheter (no open-heart surgery). It may be an option if you’re at intermediate-to-low surgical risk and meet heart ultrasound/CT measurements.
This trial tests if adjusting heart failure medications after a valve repair can help people with heart failure and a weak heart pump. It aims to find the best treatment plan to improve outcomes.
This trial compares two blood thinners (ticagrelor and aspirin) to see which one works better at preventing blood clots after a less-invasive heart valve replacement (TAVI). It is for people with severe aortic stenosis who also have diabetes, heart disease, or artery disease.
Hear when a new Aortic Valve Stenosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.